Metoprolol Tartrate Market, by Route Of Administration (Tablets and Injectable), by Application (Hypertension, Cardiovascular, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Sep 2022

Code : CMI5256

Pages :197

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

Product recall for metoprolol tartrates

Global Metoprolol Tartrate Market – Restraints

Product recall for metoprolol tartrates may hamper the global metoprolol tartrate market over the forecast period. For instance, on September 9, 2020, Aurobindo Pharma USA Inc., a manufacturing company of pharmaceutical announced the recall of a single lot of 2820 packaging bottles containing metoprolol tartrate tablets after receiving reports that a metal wire was found in a tablet, Aurobindo Pharma USA voluntarily initiated the recall. The U.S. food and drug administration (FDA) designated the recall Class II on September 20, 2021.

Global Metoprolol Tartrate Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to drive the global metoprolol tartrate market growth, owing to research and development of metoprolol tartrate for treatment of cardio logical complications associated with COVID-19 patients. For instance, on September 7, 2021, an article published in the science direct journal, a database of references and abstracts of life science research stated about the effect of metoprolol on patient of COVID-19 at pilot trial which concluded that intravenous metoprolol administration to patients with COVID-19–associated Acute Respiratory Distress Syndrome (ARDS) was safe and reduced exacerbated lung inflammation, and improved the oxygenation. Repurposing metoprolol for COVID-19–associated ARDS appeared to be a safe and inexpensive strategy that can alleviate the burden of the COVID-19 pandemic.

Increasing prevalence of hypertension is expected to drive the global metoprolol tartrate market growth over the forecast period.

Increasing prevalence of hypertension is expected to increase the use of beta blocker medications such as metoprolol tartrate, which is expected to drive the market growth over the forecast period. For instance, on September 27, 2021, according data published by The Centers for Disease Control and Prevention (CDC) stated that in 2019, around half number of adults population in the U.S which is around 116 million were suffering from hypertension which indicated by diastolic blood pressure higher than 80 mmHg, a systolic blood pressure more than 130 mmHg or are taking medication and treatment for hypertension.

Increasing product launch by market players is expected to drive the global metoprolol tartrate market growth over the forecast period.

The increasing product launch by market players is expected to drive the global metoprolol tartrate market growth over the forecast period. For instance, on April 11, 2016, Mylan N.V, a manufacturing company of generic medicines and specialty pharmaceuticals announced the launch of Metoprolol Tartrate Tablets United States Pharmacopeia (USP) which is standard quantity of drug substance or ingredient in form of 37.5 mg tablets and 75 mg tablets, which is the generic version of Lopressor Tablets developed by Novartis. As Metoprolol Tartrate Tablets USP strengths are available in form of 25 mg, 50mg, and 100 mg and these new strengths of 37.5 mg and 75 mg tablets will be a new addition to the metoprolol tartrate market.